Brief: Newron Pharmaceuticals: Valeo Pharma and Zambon form partnership for Parkinson's disease treatment Xadago in Canada
11/04/2017 07:05
April 11 (Reuters) - Newron Pharmaceuticals Spa NWRN.S
* Valeo Pharma and Zambon form partnership for Parkinson's
disease treatment Xadago (safinamide) in Canada
Source text for Eikon: ID:nNDL52qVYn
Further company coverage: NWRN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study